Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Sino Biopharmaceutical ( (HK:1177) ) has issued an update.
Sino Biopharmaceutical announced that subsidiary Chia Tai Tianqing has presented preclinical data for TQF6422, a fully human ActRII A/B monoclonal antibody, at the European Congress on Obesity 2026. The drug is designed to promote skeletal muscle growth while enhancing fat breakdown, aiming to deliver simultaneous fat loss and muscle gain.
In animal models, TQF6422 showed more than tenfold higher in vitro activity than comparable candidates, strong fat reduction and lean mass preservation at lower doses, and notable synergy when combined with semaglutide, including markedly greater fat loss and better maintenance of lean body mass. With a prolonged half-life, favorable safety profile, and a planned clinical trial application, TQF6422 positions the group in the emerging field of next-generation obesity therapies that prioritize “high-quality” weight loss, while its broader weight-loss pipeline, including an INHBE siRNA and an oral GLP-1RA approved for trials in China and the U.S., underscores its ambition to compete in the fast-growing global obesity treatment market.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$8.70 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
More about Sino Biopharmaceutical
Sino Biopharmaceutical Limited is a Hong Kong-listed pharmaceutical group focused on innovative drug research and development, particularly in therapeutic areas such as metabolic diseases. Through subsidiaries including Chia Tai Tianqing Pharmaceutical Group, it is building a portfolio in the global weight-loss and diabetes markets, targeting long-acting and higher-quality treatment options for obese and overweight patients.
Average Trading Volume: 73,169,116
Technical Sentiment Signal: Buy
Current Market Cap: HK$103.3B
See more insights into 1177 stock on TipRanks’ Stock Analysis page.